It is exciting to think that the early cohort pati

It is exciting to think that the early cohort patients are showing positive effects, maybe nothing dramatic yet in the way of tumor reduction or p21 indication, but nevertheless overall health seems to be improving.  I can only dream that this is the reason for the shut down in PR's regarding trial progression.  If this is in anyway true, it will interesting to see how DF handles ASCO as they can't be too positive too early yet how would they explain if all the patients are still alive?

Aimed toward bioman, you and I both have indicated we thought ASCO was going to be a great lead in to the merits of Kevetrin as shown by the current trial but now I am hedging my  belief that if DF is seeing positive results for K they will keep it subdued at ASCO and wait until the bag is not half  or 1/3 full but will wait til it is completely full before announcing the blockbuster news to the world in general.  Do you still think ASCO will provide fireworks for Kevetrin or just hint at what may be coming down the road?